Production Of A Novel Humanised Anti Dendritic Cell Therapeutic Antibody For Graft Versus Host Disease
Funder
National Health and Medical Research Council
Funding Amount
$202,500.00
Summary
A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be use ....A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.Read moreRead less
Dynamic In Vivo Size & Shape Measurement Of The Human Upper Airway Using Endoscopic Long-range Optical Coherence Tomogra
Funder
National Health and Medical Research Council
Funding Amount
$184,250.00
Summary
This project will fund the construction of a clinically deployable prototype device to measure changes in upper airway size and shape in patients with obstructive sleep apnoea. We have recently developed and validated a technique based on endoscopic optical coherence tomography (OCT). Preliminary in vivo studies have been performed in the human upper airway and the results published. To our knowledge, this is the only such system world-wide capable of making these important measurements. The tec ....This project will fund the construction of a clinically deployable prototype device to measure changes in upper airway size and shape in patients with obstructive sleep apnoea. We have recently developed and validated a technique based on endoscopic optical coherence tomography (OCT). Preliminary in vivo studies have been performed in the human upper airway and the results published. To our knowledge, this is the only such system world-wide capable of making these important measurements. The technique has wide commercially applicability as it can be used to measure the internal dimensions of any hollow organ system.Read moreRead less
Development Of Quantitative Tools For Assessment Of Regional Cardiac Function By Echocardiography
Funder
National Health and Medical Research Council
Funding Amount
$209,430.00
Summary
The application of ultrasound imaging to the assessment of cardiac function (echocardiography) is an invaluable tool for the assessment of patients with known or suspected cardiac problems. The assessment of contraction in each region of the heart is probably the most important of the reasons for doing this test, as regional function is disturbed in patients with coronary artery disease, which is one of the most common causes of death in Australia. The problem is that this analysis is currently ....The application of ultrasound imaging to the assessment of cardiac function (echocardiography) is an invaluable tool for the assessment of patients with known or suspected cardiac problems. The assessment of contraction in each region of the heart is probably the most important of the reasons for doing this test, as regional function is disturbed in patients with coronary artery disease, which is one of the most common causes of death in Australia. The problem is that this analysis is currently completely subjective, and the reliability of the tool is based upon the availability of an experienced observer. This is particularly a problem in rural Australia, as most specialists with expertise in this modality work in the capital cities, and especially a problem in Queensland, where fewer than half of the population live in the capital. The cardiac imaging group at the University of Queensland have been working in collaboration with GE-Vingmed Ultrasound to develop a quantitative technique for the assessment of regional cardiac function since 1997. This collaboration has been the source of a number of published papers and presentations at international meetings. Our group is considered to be a world leader in the field and our industry partner is clearly the most focused of its competitors in addressing this problem. This submission seeks to address several remaining problems. The data thus far addressed function during stress, when the condition of most patients is similar. Tissue velocities are more variable at rest, and a more sophisticated approach is required to accurately measure the lower velocities in the resting state. This research plan seeks support for the development of a new, high frame-rate acquisition that would facilitate the examination of velocities relative to each other, so that translational motion of the heart does not influence the reading. This new method would then be validated against other techniques for assessing function and disease.Read moreRead less
Phase 1 Clinical Trial Of Autologous Dendritic Cells To Induce Antigen-specific Tolerance
Funder
National Health and Medical Research Council
Funding Amount
$165,125.00
Summary
We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their ....We have previously generated modified dendritic cells in mice with the ability to suppress immune responses once they have started. This project will develop the dendritic cell vaccine as a platform technology for human clinical use. We aim to demonstrate, in a phase I clinical trial, the capacity of modified human autologous dendritic cells to suppress the immune response to a model antigen in a group of healthy volunteers and a group of patients with rheumatoid arthritis taking drugs for their diseaseRead moreRead less
Development Of Novel Anti-cancer And Immunosuppressive Drugs Derived From Pineapple Stems
Funder
National Health and Medical Research Council
Funding Amount
$469,500.00
Summary
We have discovered two molecules from pineapple stems that show anti-tumour activity in laboratory studies. One molecule, called ananain, blocks a cancer causing protein called Ras, which is defective in approximately 30% of all cancers. The other molecule, called canizain, stimulates the bodies own immune system to target and kill cancer cells. The proposed research seeks to provide proof of concept of the use of ananain and canizain as drug development targets. Once this early proof of princip ....We have discovered two molecules from pineapple stems that show anti-tumour activity in laboratory studies. One molecule, called ananain, blocks a cancer causing protein called Ras, which is defective in approximately 30% of all cancers. The other molecule, called canizain, stimulates the bodies own immune system to target and kill cancer cells. The proposed research seeks to provide proof of concept of the use of ananain and canizain as drug development targets. Once this early proof of principle phase has been completed, we believe that ananain and canizain would be extremely attractive targets for further investment by a major pharmaceutical company.Read moreRead less
Development Of Novel And Selective Anticancer Drugs Derived From Cysteine.
Funder
National Health and Medical Research Council
Funding Amount
$264,250.00
Summary
In the next few years cancer is projected to become the leading cause of death in industrialised countries. Cancer chemotherapy currently relies on destruction of tumours by toxic drugs that indiscriminately kill all cell types, resulting in side effects that limit treatment. In the 21st century new cancer drugs will more effectively destroy malignant tumour cells without damaging normal cells. The R and D herein will value-add to our discovery of a new class of potent and orally active anti-tum ....In the next few years cancer is projected to become the leading cause of death in industrialised countries. Cancer chemotherapy currently relies on destruction of tumours by toxic drugs that indiscriminately kill all cell types, resulting in side effects that limit treatment. In the 21st century new cancer drugs will more effectively destroy malignant tumour cells without damaging normal cells. The R and D herein will value-add to our discovery of a new class of potent and orally active anti-tumour drugs that possess unusually high selectivity in acting on cancer cells without killing normal human cells. Our current proof of concept will be turned into a drug development candidate that will improve our negotiating position with commercial partners.Read moreRead less
Development Of Modified IGF-binding Proteins As Novel Anti-cancer Chemotherapeutics
Funder
National Health and Medical Research Council
Funding Amount
$77,375.00
Summary
We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof ....We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof of concept in vivo in order to attract commercial funding for clinical trials.Read moreRead less
Developing Novel Anti-cancer Agens By High Throughput Chemical Screens For Small Molcules That Modulate The Pro-survival
Funder
National Health and Medical Research Council
Funding Amount
$125,000.00
Summary
Cancer is the second commonest cause of deaths in our community. Unfortunately, treatment often fails or causes unwanted side effects. This proposal seeks to discover and develop a novel class of anti-cancer drugs that act by directly activating programmed cell death (apoptosis). The Bcl-2 proteins are key regulators of cell death and by exploiting knowledge about these prime targets for cancer therapy, we aim to discover drugs that are potentially of considerable medical and commercial value.
Modulating Immune Responses By Targeting Dendritic Cells Using Dendritic Cell Specific Markers.
Funder
National Health and Medical Research Council
Funding Amount
$197,750.00
Summary
The ability to modulate immune responses would have major health benefits. Dendritic cells (DC) are key regulators of the immune system. Different types of DC possess different cell surface molecules and have differing regulatory functions. We have identified four novel DC surface molecules that can be used to target different types of DC. We aim to use antibodies against these molecules to either enhance the effectiveness of vaccines or to suppress autoimmune diseases.
Development And Prototype Manufacture Of A High-throughput CD4 T-cell Test For Management Of HIV/AIDS Infections
Funder
National Health and Medical Research Council
Funding Amount
$163,150.00
Summary
CD4 T-cells are the target of HIV-AIDS infection, and monitoring of HIV-infected patients for these cells is an essential part of disease management. Current CD4 testing methods rely on expensive equipment and reagents and high levels of training, or else they have low throughput that limits their use. This project will develop a standard laboratory assay method for testing CD4 T-cells, increasing the access of patients to CD4 testing, and to HIV therapy, worldwide.